Lacosamid

Lacosamide, the active ingredient in Lacosamid, is an anticonvulsant presented as an oral tablet for oral use. It belongs to the class of sodium‑channel modulators and is indicated for the treatment of partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency under medical supervision.

GNH USA supplies Lacosamid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality to meet the needs of healthcare providers across multiple markets.

Lacosamide is used in the management of seizure disorders, particularly within the epilepsy therapeutic pathway. - Partial‑onset seizures: reduces seizure frequency as adjunctive therapy in epilepsy patients. - Epilepsy (generalized): contributes to overall seizure control when combined with other antiepileptic drugs. - Refractory epilepsy: offers an alternative mechanism for patients not responding adequately to other treatments.

Lacosamide may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate pain in the head.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: including PR‑interval prolongation or atrioventricular block. - Hypersensitivity: anaphylactic reactions or severe rash.

Before initiating Lacosamide therapy, several safety considerations should be reviewed. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests and consider dose modification. - Cardiac conduction disorders: avoid in patients with pre‑existing PR‑interval prolongation or AV block. - Pregnancy: limited data; use only if potential benefit justifies potential risk to fetus. - Concomitant antiepileptics: assess for additive CNS depression and adjust therapy as needed. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels. - Other sodium‑channel blockers (e.g., lamotrigine, oxcarbazepine): increase risk of CNS depression and cardiac effects. - QT‑prolonging agents (e.g., amiodarone, erythromycin): may exacerbate cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: lacosamide may reduce contraceptive effectiveness; advise alternative methods. - Alcohol: combined use can enhance dizziness and sedation. - Other antiepileptic drugs: may require dose adjustments based on therapeutic monitoring.